NetworkNewsBreaks – Tonix Pharmaceuticals Holdin
Post# of 113
(Total Views: 98)
Posted On: 09/09/2024 5:55:06 PM
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Preclinical Data Demonstrating TNX-801’s Single-Dose Immune Protection Against Mpox
Tonix Pharmaceuticals Holding (NASDAQ: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, is announcing data presented at an immunology symposium at the University of Alberta. Titled “Using Synthetic Biology to Battle Mpox,” the presentation detailed positive preclinical data on Tonix’s vaccine platform, led by TNX-801, an attenuated live-virus vaccine based on synthesized horsepox, for preventing mpox (formerly known as monkeypox). TNX-801 has been shown to provide animals with single-dose immune protection against a lethal challenge with clade I monkeypox. New data also shows that TNX-801 has better tolerability than 20th century vaccinia live-virus vaccines in animals.
“We are excited to develop TNX-801 to prevent mpox and control mpox epidemics,” commented Seth Lederman, M.D., CEO of Tonix. “TNX-801 has conferred protective immunity to animals with single-dose administration. We believe TNX-801 can be manufactured at scale economically with standard shipping and storing requirements… We believe the potential of TNX-801 is supported by real world evidence based on the success of horsepox-like vaccines prior to 1900 in protecting against smallpox and containing smallpox outbreaks.”
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Tonix Pharmaceuticals Holding (NASDAQ: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, is announcing data presented at an immunology symposium at the University of Alberta. Titled “Using Synthetic Biology to Battle Mpox,” the presentation detailed positive preclinical data on Tonix’s vaccine platform, led by TNX-801, an attenuated live-virus vaccine based on synthesized horsepox, for preventing mpox (formerly known as monkeypox). TNX-801 has been shown to provide animals with single-dose immune protection against a lethal challenge with clade I monkeypox. New data also shows that TNX-801 has better tolerability than 20th century vaccinia live-virus vaccines in animals.
“We are excited to develop TNX-801 to prevent mpox and control mpox epidemics,” commented Seth Lederman, M.D., CEO of Tonix. “TNX-801 has conferred protective immunity to animals with single-dose administration. We believe TNX-801 can be manufactured at scale economically with standard shipping and storing requirements… We believe the potential of TNX-801 is supported by real world evidence based on the success of horsepox-like vaccines prior to 1900 in protecting against smallpox and containing smallpox outbreaks.”
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)